Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s):  MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines... see more

CSE:MDMA - Post Discussion

View:
Post by inviolablspirit on Nov 18, 2024 8:59pm

Pharmala

I've noticed that there is very little to no coverage of Pharmala.  It's not on any stock pick lists or in newslettters.  Even when you come across a Canadian top-performing list of junior biotech or pharmaceutical companies, Pharmala is no where to be found or mentioned.  Yet, they top almost evey company on the list in % performance this year.  So there is a lot more potential movement in this stock in the coming months and years, as it gets noticed.  

I don't mind this stock continuing to move up whille still being relatively unknown.  That will eventually change.  And once the stock gets over that 50 cent mark it will get rid of those half penny asks/bids, then it needs to get over that dollar mark for it to really get on the radar of most institutions.  As many institutional portfolios have rules that don't allow adding stocks below the $1.00 mark.  When stocks get into that $2.50 - $3.00 range that's where institutional investing really begins and positions are taken.  Unfortunately for most retail investors, that's when most have sold off their investment.   However, there's nothing wrong with solidifying your profits and possible retirement.
Comment by inviolablspirit on Nov 20, 2024 1:34am
Does anybody know if Pharmala Biotech has ever been mentioned on BNN???   Has anyone phoned in about the stock?  Just curious to hear what one of these analyst might say. Not sure if it's helpful, as many of the analyst seem self-serving.  They know they can have quite a large audience listening to their comments and picks.  At times, it seems they pump stocks when they ...more  
Comment by Chefboy69 on Nov 20, 2024 6:15am
It's very clear you're not invested here and you're looking for scalping opportunities and trading opportunities and pumping and dumping and everything else that's really truly the only thing going on in this market right now. It's truly sad and you need a group of people to help you do this. The best investments I've ever had in my life have been the one that no one knows ...more  
Comment by inviolablspirit on Nov 21, 2024 4:19pm
It's amazing how many investors begin to freak out (i.e. those on CEO) when a stock pulls back.  No stock goes straight up, there's always down days and pullbacks in there too.   So many of those investors have some unrealistic views on how stocks move day to day, week to week and month to month.   The long term technicals are strong and bullish for this stock.   If an ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities